Virpax Pharmaceuticals receives PIND application guidance from FDA for NobrXiol

Virpax Pharmaceuticals announced that it has received pre-investigational new drug, or PIND, application guidance from the FDA for NobrXiol, the company’s product candidate for the delivery of cannabidiol in the management of epilepsy in children and adults. NobrXiol utilizes the Nanomerics Molecular Envelope Technology, or MET, as its delivery system to cross the blood brain barrier, propelling the cannabidiol nanoparticles through the nose to the brain via the olfactory nerve. The main purpose of a pre-IND submission is to obtain FDA guidance on the overall development plan for a new drug and to identify any need for further data prior to submitting the IND.